Impress employers and recruiters.
Choose from hundreds of resume examples.

Target Resume Now

About the Role

We are seeking highly motivated, talented, and independent researchers to grow our diverse, innovation-focused CRISPR-X team that pioneers novel in-vivo gene editing therapies for human disease. The candidate will be focused on working with our team on developing and enabling in vivo gene insertion across multiple tissue and cell types, with the goal of advancing cutting-edge in-vivo gene editing modalities across a range of different disease indications. The successful candidate will be comfortable working with different gene editing systems, possess a strong immunology and/or synthetic immunology background, and is comfortable moving into new areas of biology as needed. The position requires enthusiasm, adaptability, attention to detail, and a desire to create new medicines for patients.

Responsibilities

Design and execute workflows of conceive, build, and assess in primary cells
Requires extensive hands-on knowledge of molecular biology strategies, including advanced cloning methods, experience in handling various primary cell types (including T cells), familiarity with delivery strategies from transfection to viral transduction to novel targeted LNP (tLNP) approaches.
Strong sense of teamwork. Collaborate with various groups within CRISPR Tx and outside vendors to advance projects from both an editing and delivery perspective, with the ultimate goal of clinical readiness.
Extensive experience in quantitative biology. Iterate on assessing editing efficiency/gene insertion, impact on cell phenotype/construct expression, and ideation of new strategies.
Design and execute ddPCR assays to quantify transgene integration efficiency
Design and execute T cell phenotyping assays such as multicolor flow cytometry panels
Leverage immunology and/or synthetic immunology background to drive innovative editing, delivery, and expression strategies
Work cross-functionally to assess editing outcomes in animal models
Analyze and present experimental data to a wide range of audiences
Generate, manage, evaluate, and maintain critical data in a highly organized manner, providing statistical analysis and troubleshooting where appropriate

Requirements

Extensive prior experience with gene editing and synthetic immunology in an academic and/or industry setting, with a track record demonstrating significant contributions.
Excellent technical skills for cloning, flow cytometry, primary T cell culturing, editing assays, and assessment of T cell phenotype and function
Experience managing multiple projects and priorities; ability to jump in to help other projects as needed
Strong communicator with a demonstrated record of being a highly collaborative team player within and across multiple departments

Skills

Gene editing
Synthetic immunology
Molecular biology strategies
Advanced cloning methods
Primary cell handling
T cell culturing
Transfection
Viral transduction
Targeted LNP (tLNP) approaches
Quantitative biology
Editing efficiency assessment
Gene insertion assessment
Cell phenotype assessment
Construct expression assessment
ddPCR assays
T cell phenotyping assays
Multicolor flow cytometry panels
Immunology
Editing strategies
Delivery strategies
Expression strategies
Animal models
Data analysis
Data presentation
Data management
Statistical analysis
Troubleshooting
In vivo delivery modalities (tLNP, AAV, VLP)
Novel editing modalities development

Location

Boston, Massachusetts
San Francisco, California

Work Type

On-site

Experience Level

Scientist II - PhD with minimum of 2-5+ years relevant experience; non-PhD with 10-12+ years progressive, relevant experience

Education Level

PhD
Degrees in Biology, Immunology, Genetics, Bioengineering, or related disciplines

Salary/Compensations

$130,000 to $140,000+ bonus, equity and benefits

Benefits

bonus
equity
benefits

About the Company

Founded over a decade ago, CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases.
The Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.
CRISPR Therapeutics is advancing a broad and diversified pipeline across hemoglobinopathies, cardiovascular, autoimmune, oncology, regenerative medicine and rare diseases.
The Company continues to expand its leadership in gene editing through the development of SyNTase™ editing, a novel and proprietary gene-editing platform designed to enable precise, efficient, and scalable gene correction.
To accelerate and expand its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals.
CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

Equal Opportunity

Pursuant to the San Francisco Fair Chance Ordinance, we will consider for employment qualified applicants with arrest and conviction records.
CRISPR Therapeutics, Inc. is committed to equal employment opportunity and non-discrimination for all employees and qualified applicants without regard to a person's race, color, gender, age, religion, national origin, ancestry, disability, veteran status, genetic information, sexual orientation or any characteristic protected under applicable law.